Hemogenyx Pharmaceuticals plc, the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the U.S. Food and Drug Administration has accepted the Company’s plan to address the FDA’s concerns that resulted in a Clinical Hold of the HEMO-CAR-T Investigational New Drug application.
